The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, hel** to …

Oligometastatic disease represents a clinical and anatomical manifestation between
localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition …

Prostate-specific membrane antigen (PSMA)–ligand PET imaging provides unprecedented
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

Background Abiraterone acetate received licencing for use in only “high-risk” metastatic
hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a …

The oligometastasis hypothesis suggests a spectrum of metastatic virulence where some
metastases are limited in extent and curable with focal therapies. A subset of patients with …

Importance Prostate radiotherapy (RT) improves survival in men with low-burden metastatic
prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it …

As medical imaging has grown progressively more complicated and subspecialized in
recent decades, several standardized reporting systems have been proposed for a variety of …

Background Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for
regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in …

18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-
pentanedioic acid), a prostate-specific membrane antigen–targeting radiotracer, has shown …